Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics Inc. has demonstrated a strong potential for growth with expectations of achieving annual sales exceeding the $500 million mark, driven by stability in the adoption of PMO products as indicated by the 4Q25 preliminary net revenue of $259.2 million. The company's management has noted that the ongoing engagement with healthcare providers is positively influencing sales outcomes, which is likely to be enhanced further by a more efficacy-focused promotional strategy moving forward. Additionally, if the initial Phase 1/2 data from the FSHD and DM1 programs in 1Q26 show competitive profiles of the siRNA candidates, it could provide significant upside potential for Sarepta's stock as it positions itself to address both ambulatory and non-ambulatory patient needs effectively.

Sarepta Therapeutics Inc. has reported preliminary 4Q25 Elevidys net revenue of $110.4 million, falling short of the consensus estimate of $117.0 million, which raises concerns about the sustainability of its revenue streams as it now reflects an annualized run-rate significantly lower than the projected $500 million sales floor. The company has seen a drastic decline in Elevidys sales, with the current exit run-rate at approximately 29% of its peak performance in 4Q24, creating uncertainties about the product's efficacy and future demand among the Duchenne muscular dystrophy population. Additionally, the sensitivity of revenue to minor operational disruptions, highlighted by the recent flu season impacting treatment schedules, underscores the fragility of Sarepta's sales base and raises alarms about its overall financial stability.